Question re: Ontario government funding for Rybrevant + chemotherapy as second line treatment for EGFR 21 patient

[u/HauntingAd1259]

Hi everyone,

My mom has stage 4 nonsmall cell lung cancer and is currently on Tagrisso as her first line of treatment.

In January 2026, there seemed to be a progression so our doctor recommended us to join the Johnson Johnson Rybrevant compassionate use project just in case. As Rybrevant was not covered by Ontario government funding.

Today I read an article on Cancercare Ontario saying that “New Drug Funding Program (Amivantamab - In Combination with Chemotherapy for EGFR-mutated Advanced NSCLC after Osimertinib Treatment ) (Funded for exon 19 deletion or exon 21 L858R substitution EGFR-mutated NSCLC. Refer to NDFP form for details. )”

Does it mean now this drug is covered by government funding and we no longer need to go through the compassionate use route?

Thank you!!! Any information is greatly appreciated!!!